WildonRFarwellMDMPH

Hospital Medicine/Hospitalist

Chief Medical Officer, Dyne Therapeutics

Dr. Farwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

TOM: Testosterone in Older Men With Sarcopenia Start of enrollment: 2005 Jan 01
Terminated
Phase 4

PubMed

119 citations
Clinical Meaningfulness of the Changes in Muscle Performance and Physical Function Associated With Testosterone Administration in Older Men With Mobility Limitation
Thomas G. Travison, Shehzad Basaria, Thomas W. Storer, Alan M. Jette, Renee Miciek
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2011-10-01
67 citations
Serum Anion Gap and Blood Pressure in the National Health and Nutrition Examination Survey
Eric N. Taylor, John P. Forman, Wildon Farwell
Hypertension. 2007-08-01
358 citations
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda, Wuh-Liang Hwu, Thomas O. Crawford
Neuromuscular Disorders. 2019-09-12

Dyne Therapies Showing Benefit for MD Patients, Per Clinical Trial DataMay 21st, 2024
Genentech Gains Clinical Development Exec by Appointing Lilli Petruzzelli; Paul Sekhri Caps Eventful Week, Naming Sapna Srivastava CFO of eGenesisMarch 5th, 2021
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical OfficerMarch 4th, 2021
Join now to see all